tiprankstipranks
Advertisement
Advertisement

Baxter International Appoints Interim CFO Amid Leadership Transition

Story Highlights
  • On March 16, 2026, Baxter CFO Joel Grade stepped down, remaining briefly as adviser.
  • Baxter named CAO Anita Zielinski interim CFO, boosted her pay, and reaffirmed 2026 outlook.
  • Looking for the best stocks to buy? Follow the recommendations of top-performing analysts.
Baxter International Appoints Interim CFO Amid Leadership Transition

Claim 30% Off TipRanks

The latest announcement is out from Baxter International ( (BAX) ).

On March 16, 2026, Baxter International announced that executive vice president and chief financial officer Joel Grade stepped down from his CFO role and moved into an advisory, non-executive position through April 30, 2026, with his departure unrelated to any disagreement with management or the board. Subject to a transition and separation agreement, Grade will receive severance consistent with the company’s executive severance plan provisions.

Effective the same day, Baxter’s board appointed senior vice president and chief accounting officer Anita Zielinski as interim CFO, adding to her existing responsibilities while the company searches for a permanent finance chief. To reflect her expanded role, Baxter granted Zielinski an additional $50,000 in monthly compensation during her interim tenure and a $250,000 restricted stock unit award vesting after three years, and the company reiterated its full-year 2026 financial outlook, signaling continuity in financial strategy despite the leadership transition.

The most recent analyst rating on (BAX) stock is a Hold with a $17.50 price target. To see the full list of analyst forecasts on Baxter International stock, see the BAX Stock Forecast page.

Spark’s Take on BAX Stock

According to Spark, TipRanks’ AI Analyst, BAX is a Neutral.

The score is held down primarily by weakening financial performance (unstable profitability and sharply deteriorated cash flow) and continued execution/margin risks highlighted in guidance (tariffs, Novum disruption, and back-half-weighted recovery). A short-term technical rebound and a moderate dividend provide partial support, but valuation remains difficult to underwrite with a negative P/E.

To see Spark’s full report on BAX stock, click here.

More about Baxter International

Baxter International Inc. is a global medtech company providing an extensive portfolio of connected solutions, medical devices and advanced injectable technologies used in hospitals, physician offices and other care settings. With about 37,500 employees, the company focuses on essential therapies and technologies that support its long-standing mission to save and sustain lives worldwide.

Its products and services position Baxter as a vital partner to healthcare providers and patients, reinforcing its role across multiple points of care in the global healthcare system. The company emphasizes operational stability, balance sheet strength and continuous improvement as it navigates industry transformation and pursues long-term value creation for its stakeholders.

Average Trading Volume: 9,729,756

Technical Sentiment Signal: Sell

Current Market Cap: $8.95B

For an in-depth examination of BAX stock, go to TipRanks’ Overview page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1